Exhibit 99.1
BELLUS Health Inc. 275 Armand-Frappier Blvd. Laval, Quebec, Canada H7V 4A7 |
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
LAVAL, Quebec – October 10, 2022 – BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming CHEST Annual Meeting, being held in Nashville, Tennessee from October 16-19, 2022.
Poster Presentation Details:
Title: Prior Specialist Consultations and Treatments in A Refractory Chronic Cough Population Enrolled in A Phase 2b Study of The P2X3 Antagonist BLU-5937
Session: Signs and Symptoms of Chest Disease
Date/Time: Tuesday, October 18th, 2022, 2:30-3:30 p.m. ET/1:30-2:30 p.m. CT